Vagus nerve stimulation — VNS — is an implanted neurostimulator that delivers intermittent electrical pulses to the left cervical vagus nerve. The pulse generator sits subcutaneously in the chest; electrodes wrap around the vagus nerve. Originally developed for refractory epilepsy, VNS was FDA-approved for treatment-resistant depression in 2005. In psychiatric practice, it remains less commonly used than ECT or TMS.
- Class
- Implanted neurostimulator
- Mechanism
- Implanted pulse generator stimulates left vagus nerve → afferent fibers carry signal to brainstem (nucleus tractus solitarius) → modulates limbic and cortical circuits via locus coeruleus, raphe nuclei
- Typical dose
- Surgically implanted device delivering intermittent electrical pulses (e.g., 30 sec on / 5 min off); titrated over months
- FDA indications
- Treatment-resistant epilepsy, treatment-resistant depression (after multiple failed antidepressant trials)
- Key adverse effects
- Voice alteration/hoarseness (during stimulation), cough, dyspnea, surgical risks, requires battery replacement every several years
Slow onset — benefits may take months to a year to emerge. Effect size modest. Used for treatment-resistant depression after multiple failed medication and psychotherapy trials. More established in epilepsy than psychiatry.
The mechanism reaches into the brain through vagal afferents. The nucleus tractus solitarius in the brainstem receives the signal and projects to locus coeruleus (norepinephrine) and raphe nuclei (serotonin), which then modulate limbic and cortical circuits. The pathway is indirect; the effect on mood is mediated through these brainstem monoaminergic systems.
Clinical character: slow onset. Benefits in treatment-resistant depression often take 6-12 months to emerge — substantially longer than ECT or TMS. The effect size is modest. For the patient and family expecting a faster timeline (as with most acute interventions), the slow course requires careful counseling. The patient who can persist through the long onset window may achieve meaningful improvement.
Indications: treatment-resistant epilepsy (well-established, primary indication); treatment-resistant depression (after multiple failed antidepressant trials). Used in psychiatry mostly in specialty centers; not common in general psychiatric practice.
Vagus nerve stimulation treats refractory depression by chronically modulating the brain through an implanted device on the vagus nerve.
Mechanism note: VNS is chronic implanted neuromodulation for severe, treatment-resistant depression — a slow-onset but durable effect, reserved for refractory illness given the surgical implantation.
Practical considerations: surgical implantation under general anesthesia. Voice alterations during stimulation (often described as hoarseness) — many patients adapt. Battery replacement every 5-10 years. Patient retains a device for life. The implantation cost and the surgical commitment are substantial.
- Cost
- Device implantation $30,000-50,000+ plus surgical fees. Replacement battery every 5-10 years.
- Generic status
- Implanted device.
- Formulary typical
- Medicare and most commercial cover for epilepsy. TRD coverage variable, often denied.
- Access friction
- Surgical implantation. Specialty programs only. Limited in psychiatric practice today.
Prescriber tip: For TRD, rarely the next step before ECT or TMS. Refer if all other modalities have failed and patient is interested in invasive option.
For most patients with treatment-resistant depression, ECT or TMS or pharmacologic approaches (esketamine, oral rapid-acting agents) precede consideration of VNS. For the highly refractory patient who has exhausted less invasive options, VNS remains a possibility at specialty centers.